Brief: Lantern Pharma Receives Notice Of US Patent Allowance For Drug Candidate LP-184 For Treatment Of Rare Pediatric Brain Cancer ATRT
14/08/2023 14:20
Aug 14 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES NOTICE OF US PATENT ALLOWANCE FOR
DRUG
CANDIDATE LP-184 FOR THE TREATMENT OF RARE PEDIATRIC BRAIN
CANCER, ATRT
Source text for Eikon: ID:nBw2JvJrFa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview